2020 ASCO Virtual Direct™ Highlights


 

2020 ASCO Update on ctDNA: Can We Use ctDNA as a Marker of MRD Following Definitive Treatment in Localized NSCLC? Is the Absence of Detectable BRAFV600 ctDNA at Baseline Associated With Improved PFS and OS in Pts Receiving Dabrafenib and Trametinib?

0 views
November 11, 2020
Comments 0
Login to view comments. Click here to Login